THYMOGLOBULIN
Drug
GENZYME CORPORATION
Total Payments
$8.1M
Transactions
3,575
Doctors
1,027
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.5M | 548 | 249 |
| 2023 | $618,523 | 490 | 196 |
| 2022 | $562,712 | 408 | 155 |
| 2021 | $742,959 | 247 | 148 |
| 2020 | $325,446 | 246 | 77 |
| 2019 | $514,708 | 454 | 166 |
| 2018 | $1.4M | 783 | 266 |
| 2017 | $1.4M | 399 | 140 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.2M | 66 | 51.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.7M | 746 | 33.0% |
| Consulting Fee | $582,667 | 126 | 7.2% |
| Travel and Lodging | $408,748 | 840 | 5.1% |
| Food and Beverage | $147,336 | 1,725 | 1.8% |
| Space rental or facility fees (teaching hospital only) | $99,850 | 40 | 1.2% |
| Education | $2,587 | 32 | 0.0% |
Payments by Type
Research
$4.2M
66 transactions
General
$3.9M
3,509 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Curative hematopoietic reconstitution for adults with treatment-na ve severe aplastic anemia using a Thymoglobulin-based Conditioning regimen for AlloBMT | SANOFI US SERVICES INC. | $1.0M | 0 |
| A Randomized, Controlled, open-labeled Clinical Trial of Thymoglobulin? Induction and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation A Multi-Center Study | GENZYME CORPORATION | $898,281 | 0 |
| A Randomized, Controlled, open-labeled Clinical Trial of Thymoglobulin Induction and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver TransplantationA Multi-Center Stud | SANOFI US SERVICES INC. | $409,318 | 0 |
| A Randomized, Controlled, open-labeled Clinical Trial of Thymoglobulin Induction and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver TransplantationA Multi-Center Study | GENZYME CORPORATION | $299,427 | 0 |
| Study Title: A Randomized, Controlled, Open- Label Clinical Trial of Thymoglobin Induction and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation | GENZYME CORPORATION | $256,652 | 0 |
| A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin in Primary Cardiac Transplant Recipients: A 12-month, single center, randomized, open-label study of efficacy comparing immediate treatment with and without Thymoglobulin | SANOFI-AVENTIS U.S. LLC | $159,924 | 0 |
| A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin in Primary Cardiac Transplant Recipients: A 12 month, single center, randomized, open-label study of efficacy comparing immediate treatment with and without Thymoglobulin 1.5 mg kg d for 5 consecutive days in heart transplant recipients. | SANOFI-AVENTIS U.S. LLC | $156,351 | 0 |
| A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin? in Primary Cardiac Transplant Recipients: A 12-month, single center, randomized, open-label study of efficacy comparing immediate treatment with and without Thymoglobulin? 1.5 mg/kg/d for 5 consecutive days in heart transplant recipients. | GENZYME CORPORATION | $156,202 | 0 |
| A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin in Primary Cardiac Transplant Recipients: A 12-month, single center, randomized, open-label study of efficacy comparing immediate treatment with and without Thymoglobulin | GENZYME CORPORATION | $90,101 | 0 |
| Optimal rabbit Anti-Thymocyte Globulin (rATG) Exposure for Adequate Immune Reconstitution in Adult Patients Undergoing Hematopoietic Cell Transplantation | SANOFI-AVENTIS U.S. LLC | $85,884 | 0 |
| Late deterioration of allograft function after kidney transplantation | GENZYME CORPORATION | $50,000 | 0 |
| Thymoglobulin induction therapy for clinical islet transplantation in an omental pouch | SANOFI US SERVICES INC. | $37,232 | 0 |
| US Health Economics Analysis of Rabbit Antithymocyte Globulin (rATG) and Basiliximab for Induction Therapy in Renal Transplantation | SANOFI-AVENTIS U.S. LLC | $4,649 | 2 |
| An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Al | SANOFI-AVENTIS U.S. LLC | $3,507 | 3 |
| the Scientific Registry of Transplant Recipients database | SANOFI-AVENTIS U.S. LLC | $1,964 | 1 |
| US Health Economics Analysis of Rabbit Antithymocyte Globulin (rATG) and Basiliximab for Induction Therapy in Renal Transplantation | SANOFI US SERVICES INC. | $1,537 | 2 |
Top Doctors Receiving Payments for THYMOGLOBULIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $4.7M | 261 |
| , M.D | Surgery | Baltimore, MD | $918,763 | 497 |
| , MD | Transplant Surgery | Cincinnati, OH | $199,623 | 119 |
| , MD | Transplant Surgery | Saint Louis, MO | $196,981 | 142 |
| , MD | Nephrology | Baltimore, MD | $167,505 | 99 |
| Jayme Locke | Surgery | Baltimore, MD | $136,886 | 68 |
| , MD,PHD | Nephrology | Saint Louis, MO | $87,358 | 81 |
| , M.D | Nephrology | Los Angeles, CA | $87,162 | 91 |
| , M.D | Surgery | New York, NY | $69,663 | 24 |
| , MD | Nephrology | Atlanta, GA | $69,452 | 52 |
| , MD | Transplant Surgery | Syracuse, NY | $67,094 | 40 |
| , MD | Surgery | Danville, PA | $54,363 | 34 |
| , M.D | Surgery | Pittsburgh, PA | $52,346 | 6 |
| , MD | Nephrology | Loma Linda, CA | $47,409 | 60 |
| , M.D | Surgery | Washington, DC | $45,899 | 15 |
| , M.D | Transplant Surgery | Houston, TX | $45,078 | 30 |
| , MD | Nephrology | Saint Louis, MO | $44,692 | 46 |
| , MD | Transplant Surgery | Hackensack, NJ | $43,114 | 24 |
| , MD, PHD | Pediatric Hematology-Oncology | New York, NY | $43,058 | 10 |
| , MD | Nephrology | Chicago, IL | $42,793 | 24 |
| , MD | Nephrology | Aurora, CO | $41,392 | 39 |
| , MD | Transplant Surgery | Boston, MA | $39,448 | 17 |
| , M.D | Surgery | Richmond, VA | $38,584 | 25 |
| , MD | Nephrology | New Haven, CT | $38,171 | 24 |
| , M.D., M.P.H | Nephrology | Fort Worth, TX | $36,156 | 34 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $3.4M
- SANOFI-AVENTIS U.S. LLC $3.2M
- SANOFI US SERVICES INC. $1.5M
Product Information
- Type Drug
- Total Payments $8.1M
- Total Doctors 1,027
- Transactions 3,575
About THYMOGLOBULIN
THYMOGLOBULIN is a drug associated with $8.1M in payments to 1,027 healthcare providers, recorded across 3,575 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2024. In 2024, $2.5M was paid across 548 transactions to 249 doctors.
The most common payment nature for THYMOGLOBULIN is "Unspecified" ($4.2M, 51.7% of total).
THYMOGLOBULIN is associated with 16 research studies, including "Curative hematopoietic reconstitution for adults with treatment-na ve severe aplastic anemia using a Thymoglobulin-based Conditioning regimen for AlloBMT" ($1.0M).